Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13462042 | 1.00 | HSD17B10 (0.46) | HSD17B10HPGDPREPTGM2NR1H2 | |
| SCHEMBL4919124 | 1.00 | HSD17B10 (0.46) | HSD17B10HPGDPREPTGM2NR1H2 | |
| SCHEMBL4913097 | 0.89 | RECQL (0.50) | HSD17B10HPGDTGM2NR1H2MEN1 | |
| SCHEMBL8426485 | 0.89 | RECQL (0.50) | HSD17B10HPGDTGM2NR1H2MEN1 | |
| SCHEMBL8272247 | 0.89 | RECQL (0.50) | HSD17B10HPGDTGM2NR1H2MEN1 | |
| SCHEMBL8272262 | 0.86 | HSD17B10 (0.48) | HSD17B10HPGDPREPTGM2NR1H2 | |
| SCHEMBL8237813 | 0.85 | PREP (0.44) | HSD17B10HPGDPREPTGM2NR1H2 | |
| SCHEMBL8426365 | 0.85 | PREP (0.44) | HSD17B10HPGDPREPTGM2NR1H2 | |
| SCHEMBL13436645 | 0.85 | PREP (0.44) | HSD17B10HPGDPREPTGM2NR1H2 | |
| SCHEMBL4919257 | 0.84 | PREP (0.47) | HSD17B10PREPTGM2NR1H2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671076-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080119464-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119464-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | DPP4, DPP3, DPP7 | HSD17B10 411/4885HPGD 1557/4885PREP 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.